Form 4: Zivo Bioscience Director Alison Cornell Reports Changes in Beneficial Ownership

Director Alison Cornell reports transactions involving Zivo Bioscience stock and options, including the cancellation of options and receipt of restricted stock.

Summary

• On June 5, 2024, Alison Cornell, a director of Zivo Bioscience, Inc., reported changes in beneficial ownership.
• Cornell acquired 60,724 shares of common stock and 95,134 shares at $7.96.
• Cornell also disposed of options to purchase an aggregate of 33,384 shares of common stock.
• In exchange for the canceled options, Cornell received 60,724 shares of restricted stock.
• The share amount and exercise price have been adjusted to reflect a 1 for 6 reverse stock split in October 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions. The acquisition of shares could be seen as slightly positive, but the cancellation of options tempers this.

Positives

• The director's acquisition of shares could be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The cancellation of stock options, while resulting in the receipt of restricted stock, could be seen as a reduction in potential future gains from stock appreciation.

Risks

• The document does not explicitly mention any risks.
• However, changes in beneficial ownership can sometimes indicate shifts in insider sentiment, which could be a risk factor to monitor.

Industry Context

This filing is a routine disclosure required by the SEC for insider transactions. It provides transparency into the trading activities of company insiders, which can be useful for investors in assessing management's view of the company's prospects.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of company performance.

Key Dates

Keywords

Zivo Bioscience, Director, Alison Cornell, Beneficial Ownership, Stock Options, Restricted Stock, Form 4, Reverse Stock Split